| __timestamp | Sarepta Therapeutics, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 49315000 | 612613000000 |
| Thursday, January 1, 2015 | 75043000 | 650773000000 |
| Friday, January 1, 2016 | 83749000 | 619061000000 |
| Sunday, January 1, 2017 | 122682000 | 628106000000 |
| Monday, January 1, 2018 | 207761000 | 717599000000 |
| Tuesday, January 1, 2019 | 284812000 | 964737000000 |
| Wednesday, January 1, 2020 | 317875000 | 875663000000 |
| Friday, January 1, 2021 | 282660000 | 886361000000 |
| Saturday, January 1, 2022 | 451421000 | 997309000000 |
| Sunday, January 1, 2023 | 481871000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Takeda Pharmaceutical Company Limited and Sarepta Therapeutics, Inc. from 2014 to 2023. Over this period, Takeda's SG&A expenses have consistently dwarfed those of Sarepta, with Takeda's 2023 expenses reaching over 1 trillion yen, a staggering 2,000% more than Sarepta's highest recorded expenses in the same year. This disparity highlights Takeda's expansive operational scale and global reach compared to Sarepta's more focused approach. Notably, Sarepta's expenses have shown a steady upward trend, increasing nearly tenfold from 2014 to 2023, reflecting its growth and investment in innovation. However, the data for 2024 is incomplete, leaving room for speculation on future trends.
Who Optimizes SG&A Costs Better? Amgen Inc. or Sarepta Therapeutics, Inc.
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: GSK plc vs Sarepta Therapeutics, Inc.
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs CymaBay Therapeutics, Inc.
Takeda Pharmaceutical Company Limited and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Mesoblast Limited Trends and Insights
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Amphastar Pharmaceuticals, Inc.
Viatris Inc. and Sarepta Therapeutics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Sarepta Therapeutics, Inc. or Amphastar Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Sarepta Therapeutics, Inc. or Taro Pharmaceutical Industries Ltd.